Loading...

You're on the old version of Simply Wall St. We will no longer be supporting this site, so we recommend you switch to our brand new platform.

Cellectar Biosciences

DB:NV4P
Snowflake Description

Adequate balance sheet and overvalued.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
NV4P
DB
$11M
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

Cellectar Biosciences, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer. The last earnings update was 28 days ago. More info.


Add to Portfolio Compare Print
  • Cellectar Biosciences has significant price volatility in the past 3 months.
NV4P Share Price and Events
7 Day Returns
-4.2%
DB:NV4P
-0.7%
DE Biotechs
-0.6%
DE Market
1 Year Returns
-47%
DB:NV4P
-13.5%
DE Biotechs
-20.9%
DE Market
NV4P Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Cellectar Biosciences (NV4P) -4.2% -40.1% -48.7% -47% -94.3% -
DE Biotechs -0.7% -7.8% -21.1% -13.5% 12.9% -11.9%
DE Market -0.6% -16.6% -26% -20.9% -25.8% -31.8%
1 Year Return vs Industry and Market
  • NV4P underperformed the Biotechs industry which returned -13.5% over the past year.
  • NV4P underperformed the Market in Germany which returned -20.9% over the past year.
Price Volatility
NV4P
Industry
5yr Volatility vs Market
Related Companies

Value

 Is Cellectar Biosciences undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Cellectar Biosciences. This is due to cash flow or dividend data being unavailable. The share price is €1.15.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Cellectar Biosciences's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Cellectar Biosciences's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:NV4P PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-12-31) in USD $-1.84
NasdaqCM:CLRB Share Price ** NasdaqCM (2020-04-03) in USD $1.18
Europe Biotechs Industry PE Ratio Median Figure of 24 Publicly-Listed Biotechs Companies 40.67x
Germany Market PE Ratio Median Figure of 401 Publicly-Listed Companies 16.45x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Cellectar Biosciences.

DB:NV4P PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqCM:CLRB Share Price ÷ EPS (both in USD)

= 1.18 ÷ -1.84

-0.64x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Cellectar Biosciences is loss making, we can't compare its value to the Europe Biotechs industry average.
  • Cellectar Biosciences is loss making, we can't compare the value of its earnings to the Germany market.
Price based on expected Growth
Does Cellectar Biosciences's expected growth come at a high price?
Raw Data
DB:NV4P PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -0.64x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 4 Analysts
-6.6%per year
Europe Biotechs Industry PEG Ratio Median Figure of 19 Publicly-Listed Biotechs Companies 1.62x
Germany Market PEG Ratio Median Figure of 256 Publicly-Listed Companies 1.16x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Cellectar Biosciences, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Cellectar Biosciences's assets?
Raw Data
DB:NV4P PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-12-31) in USD $0.84
NasdaqCM:CLRB Share Price * NasdaqCM (2020-04-03) in USD $1.18
Germany Biotechs Industry PB Ratio Median Figure of 14 Publicly-Listed Biotechs Companies 3.33x
Germany Market PB Ratio Median Figure of 572 Publicly-Listed Companies 1.44x
DB:NV4P PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqCM:CLRB Share Price ÷ Book Value per Share (both in USD)

= 1.18 ÷ 0.84

1.39x

* Primary Listing of Cellectar Biosciences.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Cellectar Biosciences is good value based on assets compared to the DE Biotechs industry average.
X
Value checks
We assess Cellectar Biosciences's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Cellectar Biosciences has a total score of 1/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is Cellectar Biosciences expected to perform in the next 1 to 3 years based on estimates from 4 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
-6.6%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Cellectar Biosciences expected to grow at an attractive rate?
  • Unable to compare Cellectar Biosciences's earnings growth to the low risk savings rate as it is expected to be loss making during the next 1-3 years.
Growth vs Market Checks
  • Unable to compare Cellectar Biosciences's earnings growth to the Germany market average as it is expected to be loss making during the next 1-3 years.
  • Unable to compare Cellectar Biosciences's revenue growth to the Germany market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
DB:NV4P Future Growth Rates Data Sources
Data Point Source Value (per year)
DB:NV4P Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 4 Analysts -6.6%
Germany Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 55.2%
Germany Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 24%
Germany Market Earnings Growth Rate Market Cap Weighted Average 14.1%
Germany Market Revenue Growth Rate Market Cap Weighted Average 4%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:NV4P Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 4 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:NV4P Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2024-12-31 23 -19 2
2023-12-31 0 -18 3
2022-12-31 0 -19 3
2021-12-31 0 -17 3
2020-12-31 0 -14 4
2020-04-06
DB:NV4P Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2019-12-31 -12 -14
2019-09-30 -12 -15
2019-06-30 -11 -16
2019-03-31 -11 -16
2018-12-31 -11 -15
2018-09-30 -12 -17
2018-06-30 -11 -15
2018-03-31 -11 -16
2017-12-31 -11 -15
2017-09-30 -11 -15
2017-06-30 -10 -14
2017-03-31 -9 -13

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Cellectar Biosciences is not considered high growth as it is expected to be loss making for the next 1-3 years.
  • Unable to determine if Cellectar Biosciences is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:NV4P Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 4 Analyst Estimates (S&P Global) See Below

All data from Cellectar Biosciences Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:NV4P Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2024-12-31 -0.35 -0.26 -0.44 2.00
2023-12-31 -0.40 -0.19 -0.60 2.00
2022-12-31 -0.55 -0.46 -0.64 2.00
2021-12-31 -0.91 -0.56 -1.46 3.00
2020-12-31 -1.28 -1.18 -1.34 3.00
2020-04-06
DB:NV4P Past Financials Data
Date (Data in USD Millions) EPS *
2019-12-31 -1.84
2019-09-30 -2.19
2019-06-30 -3.13
2019-03-31 -4.18
2018-12-31 -5.23
2018-09-30 -8.25
2018-06-30 -9.51
2018-03-31 -10.24
2017-12-31 -10.70
2017-09-30 -13.32
2017-06-30 -14.92
2017-03-31 -18.28

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Cellectar Biosciences will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess Cellectar Biosciences's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Cellectar Biosciences has a total score of 0/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has Cellectar Biosciences performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Cellectar Biosciences's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Cellectar Biosciences does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare Cellectar Biosciences's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Cellectar Biosciences's 1-year growth to the Europe Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
Cellectar Biosciences's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Cellectar Biosciences Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:NV4P Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-12-31 -14.09 5.18 8.92
2019-09-30 -14.54 5.23 7.86
2019-06-30 -15.89 5.06 7.15
2019-03-31 -15.63 4.81 7.02
2018-12-31 -15.48 4.82 6.84
2018-09-30 -17.18 4.56 8.90
2018-06-30 -15.39 4.61 9.24
2018-03-31 -15.60 4.51 9.73
2017-12-31 -15.01 4.14 9.47
2017-09-30 -15.25 4.35 7.81
2017-06-30 -14.06 4.37 6.78
2017-03-31 -13.08 4.69 5.57
2016-12-31 -9.36 4.70 4.75
2016-09-30 -2.64 4.29 4.27
2016-06-30 -2.22 3.96 4.14
2016-03-31 -2.37 3.41 4.55
2015-12-31 -5.50 3.40 5.16
2015-09-30 -9.79 3.45 5.59
2015-06-30 -7.61 3.42 5.90
2015-03-31 -7.41 3.56 5.89
2014-12-31 -8.05 3.70 5.96
2014-09-30 -8.65 4.26 6.12
2014-06-30 -10.29 4.30 6.72
2014-03-31 -10.27 4.41 6.98
2013-12-31 -10.78 4.44 6.86
2013-09-30 -8.99 3.98 6.53
2013-06-30 -10.27 4.06 5.72

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Cellectar Biosciences has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Cellectar Biosciences has efficiently used its assets last year compared to the Europe Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Cellectar Biosciences improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Cellectar Biosciences's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Cellectar Biosciences has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is Cellectar Biosciences's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Cellectar Biosciences's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Cellectar Biosciences is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Cellectar Biosciences's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Cellectar Biosciences's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Cellectar Biosciences has no debt, it does not need to be covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Cellectar Biosciences Company Filings, last reported 3 months ago.

DB:NV4P Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-12-31 9.06 0.00 10.61
2019-09-30 12.23 0.00 13.30
2019-06-30 15.99 0.00 16.85
2019-03-31 9.85 0.00 10.49
2018-12-31 13.26 0.00 13.26
2018-09-30 16.88 0.00 16.37
2018-06-30 4.71 0.00 4.18
2018-03-31 7.45 0.00 6.82
2017-12-31 10.75 0.00 10.01
2017-09-30 7.59 0.00 5.66
2017-06-30 10.86 0.00 8.31
2017-03-31 13.75 0.00 11.24
2016-12-31 13.54 0.09 11.44
2016-09-30 7.72 0.15 5.65
2016-06-30 9.83 0.21 7.92
2016-03-31 2.58 0.27 1.91
2015-12-31 1.65 0.33 3.86
2015-09-30 0.68 0.39 2.47
2015-06-30 2.37 0.45 4.83
2015-03-31 4.59 0.45 7.03
2014-12-31 6.70 0.45 9.42
2014-09-30 9.88 0.45 11.58
2014-06-30 -2.54 4.25 1.63
2014-03-31 -0.73 4.22 3.81
2013-12-31 1.70 0.45 2.42
2013-09-30 4.43 0.45 5.11
2013-06-30 5.44 0.45 5.83
  • Cellectar Biosciences has no debt.
  • Cellectar Biosciences has no debt compared to 5 years ago when it was 6.7%.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Cellectar Biosciences has less than a year of cash runway based on current free cash flow.
  • Cellectar Biosciences has less than a year of cash runway if free cash flow continues to grow at historical rates of 5.9% each year.
X
Financial health checks
We assess Cellectar Biosciences's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Cellectar Biosciences has a total score of 4/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is Cellectar Biosciences's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Cellectar Biosciences dividends.
If you bought €2,000 of Cellectar Biosciences shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Cellectar Biosciences's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Cellectar Biosciences's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:NV4P Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 4 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 1.1%
Germany Market Average Dividend Yield Market Cap Weighted Average of 315 Stocks 3.9%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.9%
Germany Bottom 25% Dividend Yield 25th Percentile 1.7%
Germany Top 25% Dividend Yield 75th Percentile 4.9%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:NV4P Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2024-12-31
2023-12-31
2022-12-31
2021-12-31
2020-12-31
2020-04-06

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Cellectar Biosciences has not reported any payouts.
  • Unable to verify if Cellectar Biosciences's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Cellectar Biosciences's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Cellectar Biosciences has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Cellectar Biosciences's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.9%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Cellectar Biosciences afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Cellectar Biosciences has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of Cellectar Biosciences's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Jim Caruso
COMPENSATION $770,012
AGE 60
TENURE AS CEO 4.8 years
CEO Bio

Mr. James V. Caruso, also known as Jim, has been the Chief Executive Officer and President of Cellectar Biosciences, Inc. since June 15, 2015. Mr. Caruso served as the Chief Commercial Officer and Executive Vice President of Allos Therapeutics Inc. from June 2006 to August 24, 2010. He served as Senior Vice President of Sales & Marketing at Bone Care International Inc. since June 2002 to May 2005 and served as Vice President, Sales from August 2002 to November 2003. He served as Head of Sales of Bone Care International Inc. since August 2002; Head of Marketing since August 2002 and Vice President- Sales from August 2002 to November 2003. He served as Executive Vice President, Chief Operating Officer since August 2010 until June 2015 and co-Founder of HIP Innovation Technology, LLC and serves as Director. He was Vice President of Sales of the Neuroscience Business Unit at Novartis from June 2001 to August 2002. He served as Vice President of Sales at BASF Pharmaceuticals from June 2000 to June 2001 and from 1988 to June 2000. He held several positions at Bristol Myers Squibb including Director of Sales- West Coast and Senior Director of Serzone Marketing. Mr. Caruso has a wide range of expertise in both drugs and devices, including a strong background in oncology. He has more than 25 years of industry experience. He has been a Director at Cellectar Biosciences, Inc. since June 15, 2015. Mr. Caruso earned his Bachelor of Science degree in Finance from the University of Nevada.

CEO Compensation
  • Jim's compensation has been consistent with company performance over the past year, both up more than 20%.
  • Jim's remuneration is higher than average for companies of similar size in Germany.
Management Team Tenure

Average tenure and age of the Cellectar Biosciences management team in years:

1.6
Average Tenure
52
Average Age
  • The average tenure for the Cellectar Biosciences management team is less than 2 years, this suggests a new team.
Management Team

Jim Caruso

TITLE
President
COMPENSATION
$770K
AGE
60
TENURE
4.8 yrs

Jarrod Longcor

TITLE
Chief Business Officer
COMPENSATION
$478K
AGE
46
TENURE
2.6 yrs

Dov Elefant

TITLE
VP & CFO
AGE
52
TENURE
0.6 yrs

Igor Grachev

TITLE
Chief Medical Officer
TENURE
0.3 yrs

Gregory Lynch

TITLE
Secretary
Board of Directors Tenure

Average tenure and age of the Cellectar Biosciences board of directors in years:

4.8
Average Tenure
60.5
Average Age
  • The tenure for the Cellectar Biosciences board of directors is about average.
Board of Directors

Doug Swirsky

TITLE
Independent Chairman of the Board
COMPENSATION
$72K
AGE
50
TENURE
2.7 yrs

Jim Caruso

TITLE
President
COMPENSATION
$770K
AGE
60
TENURE
4.8 yrs

Stephen Hill

TITLE
Independent Director
COMPENSATION
$72K
AGE
61
TENURE
13.3 yrs

Stefan Loren

TITLE
Independent Director
COMPENSATION
$72K
AGE
55
TENURE
4.8 yrs

Fred Driscoll

TITLE
Independent Director
COMPENSATION
$72K
AGE
68
TENURE
3 yrs

John Neis

TITLE
Independent Director
COMPENSATION
$72K
AGE
64
TENURE
12.2 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month open market individual insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
X
Management checks
We assess Cellectar Biosciences's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Cellectar Biosciences has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Company Info

Description

Cellectar Biosciences, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer. Its lead phospholipid drug conjugate (PDC) candidate is CLR 131, which is in Phase II clinical study in patients with relapsed or refractory (R/R) multiple myeloma (MM) and a range of B-cell malignancies, as well as in Phase I clinical study for R/R MM. The company also develops CLR 1900, a PDC chemotherapeutic program that is targeted to treat solid tumors. It has collaborative PDC programs with Pierre Fabre to develop CLR 1800 Series; Avicenna Oncology GMBH to develop CLR 2000 Series; Onconova Therapeutics, Inc. to develop CLR 2100 and 2200 Series; and Orano Med to develop novel PDCs. The company was formerly known as Novelos Therapeutics, Inc. and changed its name to Cellectar Biosciences, Inc. in February 2014. Cellectar Biosciences, Inc. was founded in 2002 and is headquartered in Florham Park, New Jersey.

Details
Name: Cellectar Biosciences, Inc.
NV4P
Exchange: DB
Founded: 2002
$10,233,277
9,396,022
Website: http://www.cellectar.com
Address: Cellectar Biosciences, Inc.
100 Campus Drive,
Florham Park,
New Jersey, 07932,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqCM CLRB Common Stock Nasdaq Capital Market US USD 22. Mar 2011
DB NV4P Common Stock Deutsche Boerse AG DE EUR 22. Mar 2011
Number of employees
Current staff
Staff numbers
8
Cellectar Biosciences employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2020/04/06 04:21
End of day share price update: 2020/04/03 00:00
Last estimates confirmation: 2020/03/10
Last earnings filing: 2020/03/09
Last earnings reported: 2019/12/31
Last annual earnings reported: 2019/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.